Get started
ROCHE HOLDINGS AG SPN ADR EACH REP 0.125 GENUSRR

ROCHE HOLDINGS AG SPN ADR EACH REP 0.125 GENUS

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

0TDF trade ideas

Roche On stage With Mr Trump Bullish $rhhbyOn Friday, Swiss pharmaceutical company Roche (RHHBY) announced it received emergency approval from the U.S. Food and Drug Administration for the use of its new diagnostic test for Covid-19, the disease caused by the novel coronavirus that was first identified in China near the end of 2019. More specifically, the test kit can be used to detect cells of the virus itself, which is classified as SARS-CoV-2, when samples are run through Roche's fully automated cobas 6800 and 8800 systems, which are already in frequent use throughout the world. Source gurufocus
OTC:RHHBYLong
by Bullishcharts
1
Roche Holdings Bull run continues. Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. Short interest 22.17 yield 1.78%
OLong
by OTCMarketsExpert
Looking for continuation In Roche Holding AGAVERAGE ANALYSTS PRICE TARGET $38 AVERAGE ANALYSTS RECOMMENDATION overweight P/E RATIO 19 SHORT INTEREST COMPANY PROFILE Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. SOURCE SEEKING ALPHA Results from a Phase 3 clinical trial, IMvigor130, evaluating Roche's (OTCQX:RHHBY) Tecentriq (atezolizumab) plus platinum-based chemo in treatment-naive patients with locally advanced or metastatic urothelial carcinoma (bladder cancer) showed a treatment benefit compared to chemo alone. Specifically, patients receiving Tecentriq + chemo experienced a statistically significant reduction in the risk of cancer progression or death compared to patients receiving only chemo. Overall survival also appeared to favor the Tecentriq group but the data are not yet mature. No new safety signals were observed. There are four ongoing late-studies assessing Tecentriq alone or in combination with other medicines in early and advanced bladder cancer. The FDA granted accelerated approval to use Tecentriq as initial treatment in patients with advanced bladder cancer in April 2017. Full approval will be contingent on the successful outcomes of the late-stage studies.
OLong
by OTCMarketsExpert
Roche primary trenline analysis (RSI, MACD, price) [Daily]Hello Everyone, I would like to share with you my idea regarding Roche. This is not a trade advice. There are signs that stock price may increase for Roche SIX:ROG RSI (14) There is a strong primary trendline A-B on RSI, support trendline - Point A (25/Oct/2017) was the lowest RSI (14) low since 10/Aug/2011 making it very significant RSI low (6+ years) - Point B (06/Feb/2018) was consecutive RSI low after A. Primary RSI trendline A-B is established. MACD (12,26,9) There is a strong primary trendline K-L on MACD, support trendline - Point K (14/Feb/2018) lowest MACD cross-over since 12/Feb/2015 very significant MACD low (3+ years) - Point L (19/Jun/2018) was consecutive MACD cross-over after K. Primary MACD trendline K-L is established. MACD (12,26,9) There are also MACD highes Z and Y. However, these are not significant as they are only local MACD highes and trendline Z-Y is not primary. Nevertheless, fact that MACD lines crossed from bottom the trendline Z-Y in point 1 was a sign of strength. This trendline is not a support. Price line - There is primary trendline (RED) linking all-time-high from 05/Dec/2014 with high from 09/May/2017. This trenline is upper resistance. - There is non-primary trendline (ORANGE) linking high from 09/May/2017 with high from 08/Jan/2017 (none of the point is 52-week high 3-yrs high or all-time-high). Nevertheless, fact that price line crossed over ORANGE trendline in point 2 was a sign of strength. This trenline is not a support. Let's hope that Earning Report will be favorable. Please share your thoughts with me. Ziza23456
SLong
by Ziza23456
Roche primary trendline analysis [Monthly]Hello Everyone, I would like to share with you my idea regarding Roche (SIX:ROG). This is not a trade advice. There is a chance that Roche stock will continue to rise for some time and if following conditions are met, it can event break out and increase significantly. However, keep in mind that these primary trendlines are NOW resistance levels and only if broken will become supports for FUTURE corrections. Therefore, neutral strategy. 1) RSI There is an interesting setup on RSI indicator. By connecting highs on RSI: C-D-E we receive a primary RSI trend line that starts in November 2014. IF the RSI crosses over that trend line in point E there is a chance for major break out and price my increase very rapidly to the upside. Line A-B-C is even better primary trend line, to watch out in the future if the RSI crosses over line C-D-E. If this happens C-D-E will become a new resistance for future corrections. 2) MACD (4,9,3) - 12,26,9 is a default setup for MACD, but it much slower. On MACD there is a trend line K-L that was crossed over in M starting a break-out form 235 in early 2017 to 265 in May 2017. This high on MACD (point of cross over on MACD) from May 2017 is point N that became part of new primary trendline K-N to watch for in nearest future if the price point P is approaching K-N trendline. 3) On MACD (4,9,3) MACD lines crossed over each other in point O giving a solid buy signal (June 2018) - watch out for sell signal on MACD 4) Price line Current price (July 2018) approaches point 5 that is a part of primary trendline 3-4-5 (with 3 being a 52-Week high). If this trend line is crossed it may allow a major break out to the upside. If that happens line 1-2-3 will be a resistance trendline, but if crossed could also begin a rally up. I hope that Earning Report will be favorable. If yes, it may give a slight push and on RSI there will be a break-out (point E) that will soon follow on other indicators giving fuel for price increase. Please share your thoughts with me. Ziza23456
S
by Ziza23456